Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage MSP16
- Development stage
- Preclinical
- Lead developer
- Centro Universitário São Camilo
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Bacteriophage MSP16 is a temperate bacteriophage belonging to the genus *Fibralongavirus* within the *Siphoviridae* family [P2690]. It was isolated from canine skin swabs and veterinary clinic wastewater in Brazil [P2690]. MSP16 exhibits broad-spectrum lytic activity against methicillin-resistant *Staphylococcus pseudintermedius* (MRSP) strains, which are major causes of canine skin and wound infections [P2690]. The phage genome encodes a holin-endolysin lysis system and anti-CRISPR (Acr) proteins that facilitate evasion of bacterial defense mechanisms [P2690]. MSP16 is under preclinical development for the treatment and management of MRSP infections in companion dogs, demonstrating both biofilm prevention and degradation capabilities [P2690].
- Other names
- Staphylococcus phage MSP16phage MSP16
Beyond the preview
Go deeper on bacteriophage MSP16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage MSP16.